AstraZeneca to buy Arrow for $150M in cash
Anglo-Swedish drug major AstraZeneca has agreed to acquire privately-held UK biotechnology firm Arrow Therapeutics for $150.0 million in cash, subject to debt and working capital adjustment. The transaction, which is expected to close early in 2007, will bolster AstraZeneca's portfolio of anti-infectives and fits its decision to re-focus its disease area research with infection and antibacterials. Arrow's antiviral prorgams include two hepatitis C virus drugs which both target the novel NS5a protein, including A-831, which is in Phase I tests, as well as Arrow's most advanced compound, currently in Phase II development and partnered with Novartis. RSV604 is a first-in-class, small-molecule, oral drug for respiratory syncytial virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze